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SCIENTIFIC OPINION 
Statement on the safety of ‘Cetyl Myristoleate Complex’ as an ingredient in 
food supplements
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
was asked to update its opinion on the safety of ‗Cetyl Myristoleate Complex‘ (CMC) as a novel food ingredient 
in the light of additional information submitted by the applicant. In its previous opinion of 2010, the Panel 
concluded that the safety of CMC as an ingredient in food supplements at an intake of 3.3 g per day has not been 
established.  This  conclusion  was  based  on  the  considerations  that  in  the  absence  of  appropriate  data  on 
absorption, distribution, metabolism and excretion, the provided toxicological data were insufficient. In 2012, 
the Commission requested EFSA to review and update its opinion by taking into account a new subchronic 90-
day oral toxicity study conducted with ―Cetylated Fatty Acid Esters Powder 50 %‖ in mice. In its opinion of 
2013, the Panel considered that a new 90-day study cannot serve as a reliable source of information supporting 
the absence of adverse effects of CMC. The dossier of this new mandate contains three new references which 
were not submitted and hence not considered in the previous assessments. The Panel notes that two references 
do not address the concerns expressed by the Panel in its previous assessments. The third reference provided is a 
report on an in vitro hydrolysis study demonstrating a low rate of hydrolysis of cetyl myristoleate and cetyl 
myristate. The Panel notes the low rate of hydrolysis of the two esters found in this in vitro hydrolysis study and 
therefore reiterates the need for adequate safety information on the unhydrolysed esters contained in CMC as 
expressed  in  its  opinions  of  2010  and  2013.  The  Panel  concludes  that,  even  after  considering  the  newly 
submitted information, the safety of ‗Cetyl Myristoleate Complex‘ has not been established. 
© European Food Safety Authority, 2014 
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SUMMARY 
‗Cetyl Myristoleate Complex‘ (CMC) consists of 50 % cetylated fatty acids (CFAs), 48 % corn starch 
and 2 % silicon dioxide. The applicant proposed a daily intake of 3.3 g CMC (1.65 g CFAs) which 
contains  approximately  660 mg  of  both  cetyl  myristoleate  and  cetyl  myristate,  the  two  main 
compounds of CMC.  
In 2009, the European Commission asked EFSA to carry out an assessment of the safety of ‗Cetyl 
Myristoleate Complex (CMC)‘ with an intended daily intake of 3.3 g per person per day in the context 
of  Regulation (EC)  No  258/97.  In  2010,  the  Panel  on  Dietetic  Products,  Nutrition  and  Allergies 
(NDA) concluded that, based on the available data, the safety of CMC has not been established 
(EFSA NDA Panel, 2010). This conclusion was based on the considerations that, in the absence of 
appropriate data on absorption, distribution, metabolism and excretion, the provided toxicological data 
were insufficient.  
In 2012, the Commission requested EFSA to review and update its opinion by taking into account a 
report of a new subchronic 90-day oral toxicity study conducted with ―Cetylated Fatty Acid Esters 
Powder 50 %‖ (Cetyl Myristoleate Complex, CMC) in mice (CMC Study Report, 2012). In 2013, the 
NDA Panel noted that the new 90-day study and its report have many shortcomings, and considered 
that this study cannot serve as a reliable source of information supporting the absence of adverse 
effects of CMC (EFSA, 2013). The Panel also noted that apart from information on the safety of the 
hydrolysis  moieties,  and  in  the  absence  of  sufficient  data  with  respect  to  kinetics  of  hydrolysis, 
adequate safety information on the parent compounds of CMC remains relevant. The Panel reiterated 
its  previous  conclusion  from  2010  that the  safety of  ‗Cetyl  Myristoleate  Complex‘  has not been 
established. 
Following a request from the European Commission, the NDA Panel was asked in 2014 to update its 
opinion on the safety of ‗Cetyl Myristoleate Complex‘ (CMC) with an intended daily intake of 3.3 g 
per person as a  novel food ingredient in food supplements in the light of  additional information 
provided by the applicant.   
The dossier of this new mandate contains three new references which were not submitted and hence 
not considered in the previous assessments. The Panel notes that two references do not address the 
concerns expressed by the Panel in its previous assessments, i.e. the absence of sufficient data with 
respect to kinetics of hydrolysis, the limitations and shortcomings of the toxicological data for CMC, 
and the safety of the parent compounds, i.e. cetylated fatty acids, mainly cetyl myristoleate and cetyl 
myristate. 
The  third  reference  is  a  study  report  on  an  in  vitro  hydrolysis  study  demonstrating  that  cetyl 
myristoleate and cetyl myristate are to a large extent resistant to hydrolysis in simulated digestive 
fluids. The Panel notes the low rate of hydrolysis of the two esters found in a newly provided in vitro 
hydrolysis study and therefore reiterates the need for adequate safety information on the unhydrolysed 
esters contained in CMC as expressed in its opinions of 2010 and 2013.  
The Panel concludes that, even after considering the newly submitted information, the safety of ‗Cetyl 
Myristoleate Complex‘ has not been established. Safety of ‗Cetyl Myristoleate Complex‘ 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 9 July 2010, EFSA adopted a Scientific Opinion on the safety of ‗Cetyl Myristoleate Complex‘ as 
a novel food ingredient (EFSA, 2010). The conclusion of the EFSA Opinion was that the safety of 
Cetyl Myristoleate Complex has not been established.  
On  12  June  2012,  the  Commission  requested  EFSA  to  review  this  Opinion  based  on  the  new 
information provided by the applicant. On 31 May 2013, EFSA adopted a statement reiterating its 
view that the safety of the product could not be established. 
The applicant has now provided additional information on the product. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002, the European Commission asks 
the EFSA to revise and update its scientific Opinion on Cetyl Myristoleate Complex in light of the 
additionally submitted information. 
 Safety of ‗Cetyl Myristoleate Complex‘ 
 
EFSA Journal 2014;12(7):3758  5 
ASSESSMENT 
1.  Introduction 
In 2009, the European Commission asked EFSA to carry out an assessment of the safety of ‗Cetyl 
Myristoleate  Complex  (CMC)‘  with  an  intended  daily  intake  of  3.3 g  per  person  from  food 
supplements in the context of Regulation (EC) No 258/97. In 2010, the Panel concluded that, based on 
the available data, the safety of CMC has not been established (EFSA NDA Panel, 2010). 
This conclusion was based on the considerations that (i) a provided rat study on the absorption and 
distribution of 
14C-labelled cetylated fatty acids (CFAs) had limitations in the design and the test 
substance used with respect to the proposed novel food ingredient, (ii) no information was provided on 
the extent of intestinal hydrolysis of the CFAs after oral intake, (iii) limited information was provided 
on the distribution of absorbed unhydrolysed CFAs and (iv) no information was provided on the 
metabolism and excretion of such intact CFAs. In the absence of appropriate data on absorption, 
distribution,  metabolism  and  excretion  (ADME),  the  provided  toxicological  data  were  considered 
insufficient. No subchronic oral toxicity study and no chronic toxicity study conducted with cetyl 
myristoleate or CMC had been provided in the original dossier.    
In 2012, the Commission requested EFSA to review and update its 2010 opinion by taking in account 
a report of a new subchronic 90-day oral toxicity study conducted with ―Cetylated Fatty Acid Esters 
Powder 50 %‖ (Cetyl Myristoleate Complex, CMC) in mice (CMC Study Report, 2012). In 2013, the 
Panel noted that the new 90-day study and its report have many shortcomings and considered that this 
study cannot serve as a reliable source of information supporting the absence of adverse effects of 
CMC (EFSA, 2013). The Panel also noted that apart from information on the safety of the hydrolysis 
moieties, and in the absence of sufficient data with respect to kinetics of hydrolysis, adequate safety 
information on the parent compounds of CMC remained relevant. The Panel reiterated its conclusion 
from 2010 that the safety of ‗Cetyl Myristoleate Complex‘ has not been established. 
‗Cetyl Myristoleate Complex‘ consists of 50 % cetylated fatty acids, 48 % corn starch and 2 % silicon 
dioxide.  The  applicant  proposed  a  daily  intake  of  3.3 g  CMC  (1.65 g  CFAs),  which  contains 
approximately 660 mg of both cetyl myristoleate and cetyl myristate, the two main compounds of 
CMC.  
2.  Additional information provided 
The dossier of this new mandate contains three new references which were not submitted and hence 
not considered in the two previous opinions.  
One study provides analytical data on the fatty acid composition of human adipose tissue (Insull and 
Bartsch, 1967). This article reports that myristic and myristoleic acid occur naturally in human adipose 
tissue at proportions of about 2.5–3 % and 0.5–0.7 % of its fatty acids. 
One review (CIR, 1988) provides an overview on toxicological studies with cetyl alcohol, which 
included studies on inhalation toxicity, acute and subchronic dermal toxicity, skin irritation, mucous 
membrane  irritation,  ocular  irritation,  acute  oral  toxicity  and  mutagenicity.  This  review  also 
summarised human studies on skin irritation and sensitisation and photosensitisation.  
The Panel notes that these two studies do not address the concerns expressed by the Panel in its 
previous assessments, i.e. the absence of sufficient data with respect to kinetics of hydrolysis, the 
limitations  and  shortcomings  of  the  toxicological  data  for  CMC  and  the  safety  of  the  parent 
compounds, the CFAs, mainly cetyl myristoleate and cetyl myristate. 
The third reference provided is an unpublished report on an in vitro hydrolysis study (Redaelli, 2010). 
This study investigated the stability of the two main constituents of CMC, cetyl myristoleate and cetyl 
myristate, in the presence of physiological fluid simulants such as saliva, gastric and intestinal juice Safety of ‗Cetyl Myristoleate Complex‘ 
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simulants  at  body  temperature.  Gas  chromatography  was  used  to  quantify  the  content  of  the 
anticipated hydrolysis products: myristic acid, myristoleic acid and cetyl alcohol. 
The  study  reported  that  cetyl  myristoleate  and  cetyl  myristate  are  to  a  large  extent  resistant  to 
hydrolysis in the simulated digestive fluids. When treated with saliva and gastric fluid simulants, after 
four hours the maximum hydrolysis rates for both compounds were ≤ 5 %; when treated with the 
intestinal fluid simulant, after four hours the maximum hydrolysis was about 8 %. 
The applicant also claims a ―history of safe use‖ of CMC and states that  EHP Products Inc., the 
manufacturer of CMC, and its affiliates have produced and sold over 95 000 kg CMC for animal and 
human use (compared with 10 000 kg up to 2008, as stated in the dossier considered by EFSA for its 
opinion of 2010). The Panel considers that sales figures do not address safety concerns. 
DISCUSSION 
The Panel notes the low rate of hydrolysis of the two esters found in a newly provided  in vitro 
hydrolysis study and therefore reiterates the need for adequate safety information on the unhydrolysed 
esters contained in CMC as expressed in its opinions of 2010 and 2013 (EFSA NDA Panel, 2010, 
2013).  
CONCLUSION 
The Panel concludes that also after considering the newly submitted information, the safety of ‗Cetyl 
Myristoleate Complex‘ has not been established. 
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ABBREVIATIONS 
ADME  absorption, distribution, metabolism and excretion 
CFA(s)  cetylated fatty acid(s) 
CMC  Cetyl Myristoleate Complex 